Harris et al Cancer 2002; Batist et al JCO 2001; Chan et al Ann Oncol 2004; Myocet EMA 2015
•
LD improves the therapeutic index of doxorubicin by reducing cardiotoxicity and provides
comparable antitumor efficacy as first-line therapy for MBC
Lifetime dose of
doxorubicin to a
cardiotoxicity
endpoint
Reduced cardiotoxicity & comparable efficacy with liposomal vs
conventional doxorubicin
